<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00336505</url>
  </required_header>
  <id_info>
    <org_study_id>CL05-001</org_study_id>
    <nct_id>NCT00336505</nct_id>
  </id_info>
  <brief_title>Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)</brief_title>
  <official_title>A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin (BIAXIN® Filmtab®) 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Life Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of cethromycin to clarithromycin for the
      treatment of mild to moderate community-acquired pneumonia (CAP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lower respiratory tract infections remain one of the leading causes of death worldwide.
      Increasing rates of antibiotic resistance and newer, more pervasive pneumonia-causative
      pathogens contribute to this statistic. Currently available macrolide antibiotics for the
      treatment of community-acquired pneumonia are slowly losing effectiveness, resulting in the
      need to develop newer drugs to fight resistant infections. In this study, we compare the
      safety and efficacy of a common macrolide, clarithromycin, to a new ketolide, cethromycin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cures in the Intent to Treat Population</measure>
    <time_frame>Test of Cure Visit, defined as 14-22 days after the first dose of study drug.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Cures in the Per Protocol Clinically Evaluable Population</measure>
    <time_frame>Test of Cure Visit, defined as 14-22 days after the first dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacteriologic Cures in the Intent to Treat Population</measure>
    <time_frame>Test of Cure Visit, defined as 14-22 days after the first dose of study drug.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriologic Cures in the Per Protocol Clinically Evaluable Population</measure>
    <time_frame>Test of Cure Visit, defined as 14-22 days after the first dose of study drug.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">584</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cethromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cethromycin</intervention_name>
    <description>Cethromycin 300 mg once per day (QD) for 7 days, administered orally</description>
    <arm_group_label>Cethromycin</arm_group_label>
    <other_name>Restanza</other_name>
    <other_name>ABT-773</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally</description>
    <arm_group_label>Clarithromycin</arm_group_label>
    <other_name>Biaxin</other_name>
    <other_name>Klacid</other_name>
    <other_name>Klaracid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory male or female, 18 years of age or older

          -  If female, non-lactating and at no risk or pregnancy (post-menopausal or must use
             adequate birth control)

          -  Positive Chest X-ray consistent with diagnosis of bacterial pneumonia

          -  Must be a suitable candidate for oral antibiotic therapy and must be able to swallow
             capsules intact

          -  Recent history of respiratory illness consistent with the clinical signs and symptoms
             of bacterial CAP

          -  Must be able to produce sputum

        Exclusion Criteria:

          -  Prior hospitalization within previous 4 weeks

          -  Residence at a chronic care facility

          -  Active tuberculosis (or other mycobacterial infection, empyema, lung abscess,
             pulmonary embolism, pulmonary edema, cystic fibrosis, tumor (primary or metastatic)
             involving the lung, bronchial obstruction, a history of post-obstructive pneumonia
             (chronic obstructive pulmonary disease [COPD] is not exclusionary), known or suspected
             Pneumocystis carinii pneumonia

          -  Treatment with long-acting antimicrobial agents within the last 4 weeks, treatment
             with ceftriaxone, azithromycin or dirithromycin antibiotic within the last 7 days, or
             subjects who have received more than 24 hours of treatment with other antibiotics
             within 7 days prior to study drug administration

          -  Any infection which requires the use of a concomitant antimicrobial agent

          -  History of hypersensitivity or allergic reactions to macrolide, ketolide, quinolone,
             azalide or streptogramin antimicrobials

          -  Treatment with another investigational drug within the last 4 weeks

          -  Females who are pregnant or lactating

          -  Subjects with known significant renal or hepatic impairment or disease

          -  Subjects with a history of impaired renal function

          -  Evidence of uncontrolled clinically significant cardiovascular, pulmonary, metabolic,
             gastrointestinal, neurological or endocrine disease, malignancy, or other abnormality
             (other than the disease being studied)

          -  Subjects who would require parenteral antimicrobial therapy for the treatment of
             pneumonia

          -  Any underlying disease or condition that would interfere with the completion of the
             study procedures and evaluations or absorption of the study drug

          -  Currently receiving or are likely to require any of the following medications during
             the period between 2 weeks prior to Evaluation 1 and within 24 hours after the last
             dose of study drug: astemizol (Hismanal®) or pimozide (Orap®)

          -  Currently receiving or are likely to require any of the following during the period
             from Evaluation 1 and within 24 hours after the last dose of study drug: theophylline
             or theophylline analogues (unless adequately monitored), carbamazepine, dexamethasone,
             phenobarbital, phenytoin, St. John's Wort, lamotrigine, troglitazone, warfarin and
             digitalis glycoside. Other barbiturates may be used with careful monitoring

          -  Subjects who are currently receiving or who are likely to require any of the following
             medications during the period between Evaluation 1 and 4: other systemic antibiotic
             therapy, rifampin or rifabutin

          -  Immunocompromised subjects, subjects receiving immunosuppressive agents, subjects with
             known human immunodeficiency virus (HIV) infections and history of acquired immune
             deficiency syndrome (AIDS) defining conditions or CD4+ T-lymphocyte count &lt;200.

          -  Subject with known or suspected central nervous system (CNS) disorder that predisposes
             them to seizures/lower seizure threshold (e.g., severe cerebral arteriosclerosis,
             epilepsy)

          -  Previous treatment with cethromycin

          -  Subjects with signs of septic shock (e.g., mental confusion, severe hypoxemia, severe
             hypotension, any other condition requiring intensive care unit [ICU] admission)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A. Eiznhamer, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Advanced Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CANADA - Advanced Life Sciences</name>
      <address>
        <city>Woodridge</city>
        <state>Illinois</state>
        <zip>60517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOUTH AFRICA - Advanced Life Sciences</name>
      <address>
        <city>Woodridge</city>
        <state>Illinois</state>
        <zip>60517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USA - Advanced Life Sciences</name>
      <address>
        <city>Woodridge</city>
        <state>Illinois</state>
        <zip>60517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2006</study_first_submitted>
  <study_first_submitted_qc>June 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2006</study_first_posted>
  <results_first_submitted>September 3, 2009</results_first_submitted>
  <results_first_submitted_qc>January 29, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2010</results_first_posted>
  <last_update_submitted>January 29, 2010</last_update_submitted>
  <last_update_submitted_qc>January 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>David Eiznhamer, PhD, Executive Vice President, Clinical Development</name_title>
    <organization>Advanced Life Sciences</organization>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>Respiratory</keyword>
  <keyword>Infection</keyword>
  <keyword>Infectious</keyword>
  <keyword>Advanced</keyword>
  <keyword>Life</keyword>
  <keyword>Sciences</keyword>
  <keyword>Lung</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Cethromycin</keyword>
  <keyword>Restanza</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Biaxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Cethromycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited globally from January 2006 through October 2007.</recruitment_details>
      <pre_assignment_details>In each treatment arm, one subject was enrolled and randomized to a blinded treatment but discontinued from study prior to administration of the first dose of drug. Thus, while official enrollment totalled 584 subjects, only 582 were randomized and dosed with blinded study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cethromycin</title>
          <description>300 mg once per day (QD) for 7 days, administered orally</description>
        </group>
        <group group_id="P2">
          <title>Clarithromycin</title>
          <description>250 mg twice per day (BID) for 7 days, administered orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="291">All subjects who were randomized and dosed.</participants>
                <participants group_id="P2" count="291">All subjects who were randomized and dosed.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="254">Number of subjects completing the test of cure (TOC) visit.</participants>
                <participants group_id="P2" count="264">Number of subjects completing the test of cure (TOC) visit.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cethromycin</title>
          <description>300 mg once per day (QD) for 7 days, administered orally</description>
        </group>
        <group group_id="B2">
          <title>Clarithromycin</title>
          <description>250 mg twice per day (BID) for 7 days, administered orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="291"/>
            <count group_id="B2" value="291"/>
            <count group_id="B3" value="582"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>All subjects who were randomized and dosed.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="14.5"/>
                    <measurement group_id="B2" value="50.3" spread="16.3"/>
                    <measurement group_id="B3" value="49.5" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>All subjects who were randomized and dosed.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cures in the Intent to Treat Population</title>
        <description>Investigators evaluated subjects for a clinical response of cure, failure, or indeterminate. Cure: Improvement or return to preinfection state or lack of progression of all pulmonary infiltrates, and resolution of all signs/symptoms present at enrollment. Failure: Persistence or worsening of signs/symptoms, the need for additional antibiotic, new pulmonary infection, progression of the chest radiograph, or death due to pneumonia. Indeterminate: Evaluation was not possible (lost to follow up, adverse event, major protocol violation). Indeterminates default to failure for analysis.</description>
        <time_frame>Test of Cure Visit, defined as 14-22 days after the first dose of study drug.</time_frame>
        <population>The Intent to Treat Population is defined as all subjects with a confirmed diagnosis of community acquired pneumonia who took at least one dose of study medication. Subjects without a radiologist-confirmed chest X-ray for pneumonia were not included in the efficacy populations.</population>
        <group_list>
          <group group_id="O1">
            <title>Cethromycin</title>
            <description>300 mg once per day (QD) for 7 days, administered orally</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin</title>
            <description>250 mg twice per day (BID) for 7 days, administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cures in the Intent to Treat Population</title>
          <description>Investigators evaluated subjects for a clinical response of cure, failure, or indeterminate. Cure: Improvement or return to preinfection state or lack of progression of all pulmonary infiltrates, and resolution of all signs/symptoms present at enrollment. Failure: Persistence or worsening of signs/symptoms, the need for additional antibiotic, new pulmonary infection, progression of the chest radiograph, or death due to pneumonia. Indeterminate: Evaluation was not possible (lost to follow up, adverse event, major protocol violation). Indeterminates default to failure for analysis.</description>
          <population>The Intent to Treat Population is defined as all subjects with a confirmed diagnosis of community acquired pneumonia who took at least one dose of study medication. Subjects without a radiologist-confirmed chest X-ray for pneumonia were not included in the efficacy populations.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Cures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indeterminates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The rate of clinical cure in each treatment group was calculated (number of cures/number of patient eligible for analysis). Non-inferiority will be demonstrated when the lower limit of the two-sided 95% confidence interval for the difference in the clinical cure rate at the Test-of-Cure visit between treatment groups (Cethromycin –Clarithromycin) is greater than delta, and includes zero, for both Per-Protocol (PP) and Intent-to-Treat (ITT) analyses.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Delta will be determined by the highest clinical cure-rate between the Cethromycin treatment group and the Clarithromycin treatment group, as follows: Greater than or equal to 90%, delta = -10%; Greater than or equal to 80% and less than 90%, delta = -15%, Greater than or equal to 70% and less than 80%, -20%)</non_inferiority_desc>
            <p_value>0.5667</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bacteriologic Cures in the Intent to Treat Population</title>
        <description>All bacteriologically evaluable subjects (ie., the subject had at least one, protocol-defined evaluable pathogen) who demonstrated eradication of all evaluable pathogens (S. pneumoniae, S. aureus, H. influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae, L. pneumophila).</description>
        <time_frame>Test of Cure Visit, defined as 14-22 days after the first dose of study drug.</time_frame>
        <population>Includes all Intent to Treat subjects that were bacteriologically evaluable (ie., subjects with at least 1 evaluable pathogen) who showed eradication of all evaluable pathogens.</population>
        <group_list>
          <group group_id="O1">
            <title>Cethromycin</title>
            <description>300 mg once per day (QD) for 7 days, administered orally</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin</title>
            <description>250 mg twice per day (BID) for 7 days, administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Bacteriologic Cures in the Intent to Treat Population</title>
          <description>All bacteriologically evaluable subjects (ie., the subject had at least one, protocol-defined evaluable pathogen) who demonstrated eradication of all evaluable pathogens (S. pneumoniae, S. aureus, H. influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae, L. pneumophila).</description>
          <population>Includes all Intent to Treat subjects that were bacteriologically evaluable (ie., subjects with at least 1 evaluable pathogen) who showed eradication of all evaluable pathogens.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bacteriologic Cures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cures in the Per Protocol Clinically Evaluable Population</title>
        <description>Investigators evaluated subjects for a clinical response of cure, failure, or indeterminate. Cure: Improvement or return to preinfection state or lack of progression of all pulmonary infiltrates, and resolution of all signs/symptoms present at enrollment. Failure: Persistence or worsening of signs/symptoms, the need for additional antibiotic, new pulmonary infection, progression of the chest radiograph, or death due to pneumonia. Indeterminate: Evaluation was not possible (lost to follow up, adverse event, major protocol violation). Indeterminates default to failure for analysis.</description>
        <time_frame>Test of Cure Visit, defined as 14-22 days after the first dose of study drug</time_frame>
        <population>The Per Protocol Clinically Evaluable Population included all ITT subjects who took the protocol-defined minimum therapy duration, were dosed with no other antimicrobials (unless allowed by protocol), and had no other major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Cethromycin</title>
            <description>300 mg once per day (QD) for 7 days, administered orally</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin</title>
            <description>250 mg twice per day (BID) for 7 days, administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cures in the Per Protocol Clinically Evaluable Population</title>
          <description>Investigators evaluated subjects for a clinical response of cure, failure, or indeterminate. Cure: Improvement or return to preinfection state or lack of progression of all pulmonary infiltrates, and resolution of all signs/symptoms present at enrollment. Failure: Persistence or worsening of signs/symptoms, the need for additional antibiotic, new pulmonary infection, progression of the chest radiograph, or death due to pneumonia. Indeterminate: Evaluation was not possible (lost to follow up, adverse event, major protocol violation). Indeterminates default to failure for analysis.</description>
          <population>The Per Protocol Clinically Evaluable Population included all ITT subjects who took the protocol-defined minimum therapy duration, were dosed with no other antimicrobials (unless allowed by protocol), and had no other major protocol violations</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Cures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The rate of clinical cure in each treatment group was calculated (number of cures/number of patient eligible for analysis). Non-inferiority will be demonstrated when the lower limit of the two-sided 95% confidence interval for the difference in the clinical cure rate at the Test-of-Cure visit between treatment groups (Cethromycin –Clarithromycin) is greater than delta, and includes zero, for both Per-Protocol (PP) and Intent-to-Treat (ITT) analyses.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Delta will be determined by the highest clinical cure-rate between the Cethromycin treatment group and the Clarithromycin treatment group, as follows: Greater than or equal to 90%, delta = -10%; Greater than or equal to 80% and less than 90%, delta = -15%, Greater than or equal to 70% and less than 80%, -20%)</non_inferiority_desc>
            <p_value>&gt;0.9999</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bacteriologic Cures in the Per Protocol Clinically Evaluable Population</title>
        <description>All bacteriologically evaluable subjects (ie., the subject had at least one, protocol-defined evaluable pathogen) who demonstrated eradication of all evaluable pathogens (S. pneumoniae, S. aureus, H. influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae, L. pneumophila).</description>
        <time_frame>Test of Cure Visit, defined as 14-22 days after the first dose of study drug.</time_frame>
        <population>Includes all Per Protocol Clinically Evaluable subjects that were bacteriologically evaluable (ie., subjects with at least 1 evaluable pathogen) who showed eradication of all evaluable pathogens.</population>
        <group_list>
          <group group_id="O1">
            <title>Cethromycin</title>
            <description>300 mg once per day (QD) for 7 days, administered orally</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin</title>
            <description>250 mg twice per day (BID) for 7 days, administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>Bacteriologic Cures in the Per Protocol Clinically Evaluable Population</title>
          <description>All bacteriologically evaluable subjects (ie., the subject had at least one, protocol-defined evaluable pathogen) who demonstrated eradication of all evaluable pathogens (S. pneumoniae, S. aureus, H. influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae, L. pneumophila).</description>
          <population>Includes all Per Protocol Clinically Evaluable subjects that were bacteriologically evaluable (ie., subjects with at least 1 evaluable pathogen) who showed eradication of all evaluable pathogens.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bacteriologic Cures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reported adverse events were recorded for 30 days after the last dose of study drug for individual subjects.</time_frame>
      <desc>The safety population was defined as all randomized and dosed subjects with at least one follow up safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cethromycin</title>
          <description>300 mg once per day (QD) for 7 days, administered orally</description>
        </group>
        <group group_id="E2">
          <title>Clarithromycin</title>
          <description>250 mg twice per day (BID) for 7 days, administered orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer extensive stage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="288"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="288"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="288"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="288"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Eiznhamer, PhD, Executive Vice President, Clinical Development</name_or_title>
      <organization>Advanced Life Sciences</organization>
      <phone>630-739-6744</phone>
      <email>deiznhamer@advancedlifesciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

